- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Comparative Effectiveness Of Routine Tenecteplase Thrombolysis In Acute Stroke Compared With Alteplase: An INternational Collaboration (CERTAIN Collaboration): Rates Of Symptomatic Intracranial Hemorrhage (Best of Specialty Conferences, Science and Technology Hall, Level 3; Poster Board no. 204) - Oct 5, 2022 - Abstract #AHA2022AHA_8131;
In this preliminary analysis from a large, multicenter registry, ischemic stroke treated with tenecteplase was associated with a lower rate of sICH than with alteplase. An updated analysis with patient data from additional sites will be presented at the Conference.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal, HEOR: Economic evaluation of endovascular treatment for acute ischaemic stroke in Thailand. (Pubmed Central) - Oct 5, 2022
Consistent with this weak recommendation, optimal patient management will likely often include co-treatment with intravenous alteplase, depending on local circumstances and patient presentation. EVT represents good value for money in the Thai context, both when provided to patients eligible for intravenous alteplase, and when provided alone to those who are ineligible for intravenous alteplase.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review. (Pubmed Central) - Oct 4, 2022
We provide an overview of published clinical trials studying TNK in acute ischemic stroke, including dose-escalation studies and head-to-head comparisons with tPA. Finally, we summarize current acute stroke guideline recommendations and suggest treatment algorithms to manage the two main complications of intravenous thrombolysis: symptomatic intracerebral hemorrhage and angioedema.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Baseline blood pressure does not modify the effect of intravenous thrombolysis in successfully revascularized patients. (Pubmed Central) - Oct 1, 2022
P=N/A
Studies indicate a trajectory relationship between baseline blood pressure (BP) and outcome in patients with acute ischemic stroke (AIS) eligible for both intravenous thrombolysis (IVT) with alteplase and endovascular treatment (EVT)...Future studies are needed to confirm our findings. URL: http://www.clinicaltrials.gov, Identifier: NCT03469206.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
LIPOPROTEIN(A) INTERFERES ON EARLY NEUROLOGICAL IMPROVEMENT AFTER INTRAVENOUS THROMBOLYSIS WITH ALTEPLASE (Room 332) - Oct 1, 2022 - Abstract #WSC2022WSC_826;
P=N/A
Background and Aims: Post-stroke spastic hemiparesis often requires treatment of upper limb (UL) and lower limb (LL) muscles. This real-world analysis of ASPIRE data demonstrated high patient and physician satisfaction with onabotulinumtoxinA treatment for post-stroke spastic hemiparesis.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ENDOVASCULAR TREATMENT OF ELDERLY PATIENTS AGED ≥80 WITH ACUTE ISCHEMIC STROKE (Room 332) - Oct 1, 2022 - Abstract #WSC2022WSC_531;
EVT may be performed safely and effectively in patients aged ⩾80 despite less frequent favorable outcomes. Decision-making should not withdraw based solely on high age.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
TENECTEPLASE VERSUS ALTEPLASE IN STROKE PATIENTS WITH LARGE VESSEL OCCLUSION: RESULTS FROM THE ACT TRIAL (Hall 406) - Oct 1, 2022 - Abstract #WSC2022WSC_304;
Increased reperfusion with TNK persists across the spectrum of thrombolytic-to-initial-angiographic-assessment times. Intravenous tenecteplase has similar benefit as alteplase in patients with AIS and large vessel occlusions.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
EXAMINATION OF SEX DIFFERENCES AFTER ACUTE ISCHAEMIC STROKE USING CEREBRAL IMAGING (Room 332) - Oct 1, 2022 - Abstract #WSC2022WSC_247;
There are no clear sex differences in baseline imaging findings in thrombolysed AIS patients. Further investigations are required to examine imaging biomarkers in relation to response to treatments.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
A STUDY OF DEMOGRAPHIC AND CLINICAL PROFILE OF COVID-19 RELATED STROKES (Room 332) - Oct 1, 2022 - Abstract #WSC2022WSC_228;
Neurovascular complications of COVID-19 are increasingly being recognized in developing countries, like India. Early stroke recognition and strict adherence to Protected Stroke Code may facilitate better stroke management with minimum risk of COVID-19 transmission.
- |||||||||| nerinetide (NA 1) / NoNO, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ASSOCIATION OF WHITE MATTER HYPERINTENSITY BURDEN WITH FUNCTIONAL OUTCOME AFTER EVT: GOING BEYOND CHRONOLOGICAL AGE. (Room 332) - Oct 1, 2022 - Abstract #WSC2022WSC_203;
The models were adjusted for age, sex, final infarct volume (FIV), laterality, cortical atrophy, Nerinetide-Alteplase interaction, and study site. In patients with AIS undergoing EVT within 12 hours of onset, an increasing burden of WMH assessed on CT is associated with worse functional outcome over time.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
TENECTEPLASE VERSUS ALTEPLASE IN THE REAL WORLD: UPDATED NEW ZEALAND DATA (Nicoll 2-3) - Oct 1, 2022 - Abstract #WSC2022WSC_120;
In patients with AIS undergoing EVT within 12 hours of onset, an increasing burden of WMH assessed on CT is associated with worse functional outcome over time. A forced reversion from Tenecteplase to Alteplase demonstrates that previously reported benefits from TNK in a real-world setting were not simply attributable to a concurrent temporal trend.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Retrospective data: Intrapleural thrombolytics for parapneumonic effusion: A network meta-analysis. (Pubmed Central) - Oct 1, 2022
Alteplase + DNase is likely to outperform others as it was observed with the least risk of patients referred for surgical interventions. Until additional data emerges that changes the pooled estimates, thrombolytics other than streptokinase are preferred due to increased risk of serious adverse events.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Implementation of the Helsinki Model at West Tallinn Central Hospital. (Pubmed Central) - Sep 30, 2022
In conclusion, several implemented steps enabled the shortening of the DNT from 30 to 25.2 min. Short DNTs were achieved and maintained only with EMS prenotification.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Journal: Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability: A Meta-Analysis. (Pubmed Central) - Sep 29, 2022
When compared with those without disability, there was no significant difference in the return to baseline function or sICH. High-quality data comparing treated versus untreated patients with premorbid disability are needed to clarify this issue.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: IV tPA for acute ischemic stroke in the setting of intracranial tumor: A scoping review. (Pubmed Central) - Sep 29, 2022
There is heterogeneity and risk of selection bias with the included studies, and findings are not confirmatory. Further research is indicated to assess the rate of ICH with IV tPA for AIS in the setting of brain tumor.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase. (Pubmed Central) - Sep 29, 2022
Staphylokinase nonimmunogenic variant was proven noninferior to alteplase in a clinical trial, with decreased risk of intracranial hemorrhage and the advantage of single bolus administration...This knowledge of limitations unlocks new possibilities for improvements that are now achievable by the community of protein engineers who have the required expertise and are ready to transform staphylokinase into a powerful molecule. Collectively, the noninferiority and safety of nonimmunogenic staphylokinase together with the newly identified effectivity limitation make staphylokinase a perfect candidate for further exploration, modification, and advancement to make it the next-generation widely accessible thrombolytic drug effectively treating stroke all around the world, including middle- and low-income countries.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment. (Pubmed Central) - Sep 29, 2022
Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores...Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Combined pharmacomechanical thrombectomy with selective catheter-directed thrombolysis in patients with acute proximal deep vein thrombosis. (Pubmed Central) - Sep 29, 2022
All patients received a three-step therapy: (i) insertion of a temporary inferior vena cava filter, (ii) percutaneous pharmacomechanical thrombectomy via rotational mechanical thrombectomy device with an adjuvant 0.15 mg/kg recombinant tissue-type plasminogen activator alteplase, and (iii) catheter-directed thrombolysis with continuous 1 mg/h tissue-type plasminogen activator alteplase...The 3, 6, and 12-month freedom from re-thrombosis rates were 96.3%, 92.6%, and 86.0%, respectively. Combined percutaneous pharmacomechanical thrombectomy and catheter-directed thrombolysis seems to be an effective and safe treatment of the iliofemoral acute deep vein thrombosis with acceptable minor bleeding complications post-interventionally.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Effectiveness and Safety of Tecneplase vs. Alteplase in the Acute Treatment of Ischemic Stroke. (Pubmed Central) - Sep 24, 2022
No significant differences were identified in mortality; 17.5% with rtPA and 20% with TNK (p = 0.79), nor in the appearance of intracranial hemorrhage ICH (15.2% with rtPA vs. 30% with TNK (p = 0.12). In our series, there were not significant differences shown regarding effectiveness and safety between tenecteplase and alteplase.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Observational data, Journal: Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice. (Pubmed Central) - Sep 24, 2022
Switching to tenecteplase in routine clinical practice in a 10-hospital network was associated with shorter door-to-needle time and door-in-door-out times, noninferior favorable clinical outcomes at discharge, and reduced hospital costs. Evaluation in larger, multicenter cohorts is recommended to determine if these observations generalize.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Treatments in Ischemic Stroke: Current and Future. (Pubmed Central) - Sep 24, 2022
The COVID-19 pandemic has critically stressed global healthcare systems, with collateral damage resulting in access delivery of only emergency care, such as ischemic stroke. Regarding telemedicine, it has had a minor role in acute stroke management, and with the onset of COVID-19, this role will most likely be adopted to increase access and delivery in stroke assessment, but also in the follow-up.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1. (Pubmed Central) - Sep 23, 2022
This study shows that the suboptimal fibrinolytic response in COVID-19 disease is directly attributable to elevated levels of PAI-1, which attenuate plasmin generation. These data highlight the important prognostic potential of PAI-1 and the possibility of using pre-existing drugs, such as tenecteplase, to treat COVID-19 disease and potentially other respiratory diseases.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: ORIGINAL: A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity (clinicaltrials.gov) - Sep 23, 2022
P3, N=1400, Recruiting,
These data highlight the important prognostic potential of PAI-1 and the possibility of using pre-existing drugs, such as tenecteplase, to treat COVID-19 disease and potentially other respiratory diseases. Active, not recruiting --> Recruiting | N=916 --> 1400 | Trial completion date: Dec 2022 --> Aug 2023 | Trial primary completion date: Dec 2022 --> Aug 2023
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Journal: Benefit of Intravenous Alteplase Before Thrombectomy Depends on ASPECTS. (Pubmed Central) - Sep 21, 2022
Use of IVT prior to MT in patients with an ASPECTS of <6 was not associated with a treatment benefit and should be considered carefully. ANN NEUROL 2022;92:588-595.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Implementation of an Evidence-Based Practice Change Removing Heparin From Implanted Vascular Access Devices. (Pubmed Central) - Sep 20, 2022
Alteplase administration rates were used to measure success of the project, with no statistically significant change observed in alteplase rates 6 mo postimplementation. Successful implementation of this practice change demonstrates that 0.9% sodium chloride may be used for IVAD lock when deaccessing.
|
